Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUIDIL vs ALPHADROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluidil is a thiazide-like diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis.
Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.
Hypertension,Edema associated with congestive heart failure,Edema associated with renal disease,Edema associated with hepatic cirrhosis
Adjunctive therapy for short-term administration in severe allergic reactions,Management of inflammatory and autoimmune conditions,Off-label: Treatment of certain cancers (e.g., multiple myeloma, lymphoid malignancies)
5 mg orally once daily.
0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.
Terminal elimination half-life: 1.5-2 hours (prolonged in hepatic impairment to 4-6 hours).
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Fluidil is extensively metabolized in the liver, primarily via glucuronidation and sulfation; cytochrome P450 enzymes play a minor role.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal: 60-70% unchanged; biliary/fecal: <5%; hepatic metabolism: 25-35%.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugates (20-25%); biliary/fecal excretion accounts for 5-10%.
85-92% bound to albumin, alpha-1-acid glycoprotein.
Highly protein bound (92-95%), primarily to albumin and alpha-1-acid glycoprotein.
0.8-1.2 L/kg (extensive tissue distribution).
0.8-1.2 L/kg; indicates extensive distribution into total body water with some tissue binding.
Oral: 60-80% (first-pass metabolism).
Oral: 70-80% due to first-pass metabolism; intramuscular: 90-100%.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of dose; GFR <10 m L/min: avoid use due to risk of accumulation.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: 2.5 mg once daily. Child-Pugh Class C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Not established for pediatric patients <18 years.
0.01 mg/kg intravenously every 4-6 hours; maximum 0.2 mg/kg/day.
No specific adjustment; use caution due to increased sensitivity.
Initiate with 0.25 mg intravenously every 6 hours; titrate cautiously due to increased sensitivity and renal impairment.
No FDA black box warning has been issued for Fluidil.
None
Electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia),Hypovolemia and hypotension,Hyperuricemia and gout,Azotemia and renal impairment,Sulfonamide allergy cross-reactivity
Increased risk of infections due to immunosuppression,Adrenal suppression with prolonged use,Osteoporosis with long-term use,Exacerbation of diabetes mellitus,Psychiatric disturbances
Anuria,Hypersensitivity to Fluidil or other sulfonamide-derived drugs,Hepatic coma or pre-coma,Severe electrolyte depletion
Systemic fungal infections,Hypersensitivity to the drug or any component,Administration of live or live attenuated vaccines
Avoid high-potassium foods (e.g., bananas, oranges, avocados, spinach, potatoes, salt substitutes with potassium chloride). Limit alcohol intake as it may worsen dizziness and dehydration. Grapefruit juice has not been reported to interact significantly, but caution is advised with other drugs. Maintain adequate fluid intake to prevent dehydration.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Take with food to reduce gastrointestinal irritation. Limit sodium intake to reduce fluid retention; consider potassium-rich foods.
FLUIDIL is contraindicated in pregnancy. First trimester: Associated with increased risk of major malformations, including neural tube defects and cardiac anomalies. Second and third trimesters: May cause oligohydramnios due to diminished fetal renal function; use may lead to fetal renal impairment, persistent ductus arteriosus, and craniofacial abnormalities.
ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trimester exposure can cause fetal growth restriction, oligohydramnios, and adrenal suppression. Risk category X.
Excreted in human milk; M/P ratio not established. Use is not recommended during breastfeeding due to potential for serious adverse reactions in nursing infants.
Excreted into breast milk; M/P ratio not reported. Potential for infant adrenal suppression and growth retardation. Breastfeeding not recommended during therapy and for at least 3 months after last dose.
FLUIDIL is not indicated for use in pregnancy. No dosage adjustment recommendations are available for pregnant women; avoidance is mandatory.
Avoid use in pregnancy; no established dose adjustments; use lowest effective dose if unavoidable; increased clearance may require dose increase, but teratogenicity risk precludes use.
Fluidil (a diuretic combination, e.g., hydrochlorothiazide and triamterene) may cause electrolyte disturbances; monitor potassium levels closely due to triamterene's potassium-sparing effect. Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min) or hyperkalemia. Onset of diuresis occurs within 2 hours, peak effect at 4-6 hours. Administer in the morning to prevent nocturia.
Monitor blood glucose closely in diabetic patients; may cause hyperglycemia. Administer with food to reduce GI upset. Taper dose over 1-2 weeks after prolonged use to avoid adrenal insufficiency. Avoid live vaccines during therapy.
Take this medication in the morning to reduce nighttime urination.,Avoid potassium supplements or high-potassium foods (e.g., bananas, oranges, salt substitutes) unless directed by your doctor.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or excessive thirst.,Stay hydrated but avoid excessive fluid intake; drink water as needed.,Report any rash, difficulty breathing, or swelling of the face/lips immediately.,Do not drive or operate machinery if you feel dizzy or lightheaded, especially during the first few days of treatment.
Take with food or milk to prevent stomach upset.,Do not stop taking this medication suddenly without consulting your doctor.,Report any signs of infection (fever, sore throat) or unusual bleeding/bruising.,Avoid alcohol while on this medication.,Inform all healthcare providers that you are taking Alphadrol.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUIDIL vs ALPHADROL, answered by our medical review team.
FLUIDIL is a Mineralocorticoid that works by Fluidil is a thiazide-like diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis.. ALPHADROL is a Mineralocorticoid that works by Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUIDIL and ALPHADROL depend on the specific clinical indication. These are both Mineralocorticoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUIDIL is: 5 mg orally once daily.. The standard adult dose of ALPHADROL is: 0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUIDIL and ALPHADROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUIDIL is classified as Category C. FLUIDIL is contraindicated in pregnancy. First trimester: Associated with increased risk of major malformations, including neural tube defects and cardiac anomalies. Second and thi. ALPHADROL is classified as Category C. ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.